468 related articles for article (PubMed ID: 27740868)
1. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
2. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
3. Vilaprisan for treating uterine fibroids.
Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
[TBL] [Abstract][Full Text] [Related]
4. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
5. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatment options for uterine fibroids.
Donnez J; Arriagada P; Donnez O; Dolmans MM
Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
[TBL] [Abstract][Full Text] [Related]
8. The place of selective progesterone receptor modulators in myoma therapy.
Donnez J; Donnez O; Courtoy GE; Dolmans MM
Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
[TBL] [Abstract][Full Text] [Related]
9. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
10. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
11. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
12. [Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis].
Nisolle M; Closon F; Firquet A; Top M; Pintiaux A
Rev Med Liege; 2014 Apr; 69(4):220-5. PubMed ID: 24923103
[TBL] [Abstract][Full Text] [Related]
13. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
14. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
15. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
16. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
17. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
18. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
19. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Pourcelot AG; Capmas P; Fernandez H
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis.
Kalampokas T; Kamath M; Boutas I; Kalampokas E
Gynecol Endocrinol; 2016; 32(2):91-6. PubMed ID: 26572056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]